Table 2.
The levels of inflammatory markers in PWS patients and healthy controls
| n (PWS/HCs) | PWS (n = 20) | HCs (n = 20) | p | |
|---|---|---|---|---|
| IL-1β | (20/20) | 0.4 ± 0.2 | 0.2 ± 0.1 | < 0.001 |
| IL-1RA | (20/20) | 106.6 ± 99.3 | 65.8 ± 66.5 | 0.010 |
| IL-2 | (20/20) | 2.5 ± 0.6 | 2.2 ± 0.8 | 0.213 |
| IL-4 | (20/20) | 3.9 ± 1.1 | 3.3 ± 1.1 | 0.100 |
| IL-5 | (20/19) | 6.9 ± 4.2 | 7.4 ± 4.3 | 0.687 |
| IL-6 | (19/18) | 0.4 ± 0.3 | 0.3 ± 0.2 | 0.086 |
| IL-7 | (20/20) | 12.7 ± 4.2 | 12.7 ± 4.2 | 0.988 |
| IL-8 | (20/20) | 6.9 ± 3.6 | 6.8 ± 5.2 | 0.495 |
| IL-9 | (20/20) | 164.3 ± 59.5 | 138.0 ± 70.1 | 0.314 |
| IL-10 | (18/16) | 2.15 ± 1.4 | 2.2 ± 1.1 | 0.984 |
| IL-13 | (20/20) | 2.9 ± 1.4 | 1.5 ± 0.6 | < 0.001 |
| IL-17 | (20/20) | 11.1 ± 4.3 | 11.5 ± 3.9 | 0.565 |
| IP-10 | (20/20) | 346.7 ± 239.3 | 394.1 ± 333.3 | 0.779 |
| MCP-1 | (20/20) | 32.4 ± 14.4 | 26.7 ± 13.9 | 0.208 |
| MIP-1α | (20/20) | 1.5 ± 0.7 | 2.1 ± 1.5 | 0.192 |
| MIP-1β | (20/20) | 46.8 ± 5.5 | 49.4 ± 7.2 | 0.383 |
| PDGF-BB | (20/20) | 3025.0 ± 1204.2 | 2571.8 ± 1015.7 | 0.206 |
| TNF-α | (20/20) | 11.9 ± 2.4 | 11.3 ± 2.1 | 0.277 |
| Eotaxin-1 | (20/20) | 67.0 ± 28.0 | 68.6 ± 23.1 | 0.852 |
| FGF-2 | (20/20) | 18.6 ± 3.8 | 18.6 ± 3.4 | 0.953 |
| G-CSF | (20/20) | 158.0 ± 41.2 | 170.2 ± 53.1 | 0.422 |
Data expressed as mean ± SD. The levels of inflammatory markers were represented in pg/ml
Significant differences after the Benjamini–Hochberg correction were marked with bold characters (p ≤ 0.003)
IL interleukin, IP-10 interferon-γ induced protein 10, MCP-1 monocyte chemoattractant protein-1, MIP-1α macrophage inflammatory protein-1α, MIP-1 β macrophage inflammatory protein-1β, TNF-α tumour necrosis factor α, PDGF-BB platelet-derived growth factor with two B subunits, FGF-2 fibroblast growth factor-2, G-CSF granulocyte colony-stimulating factor